[Prazosin in the treatment of hypertension: effect on lipid metabolism].
In an open, non-comparative study, the effect of Prazosin, a selective and competitive inhibitor of alpha-adrenergic receptors, on blood pressure and lipid metabolism was studied in out-patients with hypertension. The pronounced antihypertensive effect of this vasodilator was confirmed. In almost all patients, i.e. in 144 of 171 patients with monotherapy, Prazosin caused a significant decrease of diastolic blood pressure within 3 to 6 weeks (in sitting position reduction to values below 90 mm Hg). This confirms the established antihypertensive effect due to vasodilation. In addition, Prazosin therapy is associated with a significant reduction in total cholesterol (p less than 0.001), a significant increase of HDL-cholesterol (p less than 0.001), a significant reduction of triglycerides (p less than 0.01) during the study period of 26 weeks. Prazosin monotherapy had a more pronounced influence on serum lipids than the combination of Prazosin with a diuretic. Prazosin was tolerated well; only during the first treatment weeks, a higher frequency of side effects due to abrupt reduction of blood pressure was observed, closely correlating with a too rapid increase of daily dose. Due to its proven antihypertensive effect and its favorous influence on lipid metabolism, Prazosin is suited for long-term treatment of hypertension, thus reducing two major risk factors, associated with coronary heart disease.
Abteilung für Klinische Pharmakologie, I. Medizinischen Universitätsklinik Wien.
G
G
Hitzenberger
K
K
Neumann
S
S
Dietz
H
H
Egger
K
K
Hariri
E
E
Kittler
W
W
Niedrist
R
R
Nitsch-Fritz
O
O
Ravanelli
H
H
Sapinsky
D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D011224:Prazosin / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D011224:Prazosin
Prazosin in der Behandlung der Hypertonie: Einfluss auf den Lipidwechsel.